CHP
ACOR

Cable Hill Partners’s Acorda Therapeutics ACOR Stock Holding History

Cable Hill Partners’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-2
Closed -$4K – 802
2016
Q4 		$4K Sell
2
-1
-33% -$2.38K ﹤0.01% 597
2016
Q3 		$8K Hold
3
– – 0.01% 478
2016
Q2 		$10K Hold
3
– – 0.01% 378
2016
Q1 		$11K Hold
3
– – 0.01% 341
2015
Q4 		$18K Hold
3
– – 0.01% 262
2015
Q3 		$12K Hold
3
– – 0.01% 341
2015
Q2 		$14K Hold
3
– – 0.01% 377
2015
Q1 		$14K Hold
3
– – 0.01% 373
2014
Q4 		$17K Buy
+3
New +$12.9K 0.02% 324

Other funds holding ACOR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
CI
Cambiar Investors Denver, Colorado $2.16B AUM 16.24% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Cable Hill Partners's ACOR Position: Q1 2017 in Review

Cable Hill Partners sold out of Acorda Therapeutics (ACOR) in Q1 2017, closing a stake of 2 shares — an estimated $4K sold.

Cable Hill Partners first reported a position in ACOR in Q4 2014 and held it in 9 quarters. The position peaked at $18K in Q4 2015. 178 funds tracked by Wall St. Rank hold ACOR as of Q1 2017.

  • Cable Hill Partners reported no remaining Acorda Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Cable Hill Partners sold 2 Acorda Therapeutics shares in Q1 2017, an estimated $4K.
  • Cable Hill Partners first reported a position in Acorda Therapeutics in Q4 2014 and held it in 9 quarters.
  • Cable Hill Partners's Acorda Therapeutics position peaked at $18K in Q4 2015.
  • 178 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q1 2017.

Based on Cable Hill Partners's 13F filing for Q1 2017, filed 7 Apr 2017.